KOS AI has unveiled Argus, a revolutionary non-invasive blood glucose monitoring device that uses advanced optical sensing and artificial intelligence to measure blood glucose levels without needles or invasive sensors. This wrist-worn device represents a significant advancement in diabetes management technology, offering users a pain-free alternative to traditional glucose monitoring methods.
Shalal Habib, CEO of KOS AI, emphasized the transformative nature of the device: “The KOS Argus transforms glucose monitoring from a painful, intermittent process into a seamless, continuous experience. Our technology eliminates the pain and inconvenience of finger pricks while providing reliable glucose readings that can help people better manage their health.”
Abhinav Agarwal, Head of Machine Learning at KOS AI, explained the innovative approach: “We’ve pioneered a fundamentally different approach to glucose monitoring that combines multi-dimensional signal processing with advanced machine learning architectures. By analyzing subtle variations across multiple wavelengths and applying our custom-designed deep learning models, we’ve achieved a level of accuracy that was previously thought impossible without invasive sensors.”
Key features of the KOS Argus include:
Multi-wavelength photoplethysmography (PPG) technology with precision optical sensors
Sophisticated AI algorithms for accurate glucose readings
Continuous monitoring with real-time glucose readings throughout the day
Trend analysis to identify patterns and alert users to potential issues
Additional vital sign monitoring including heart rate, SpO2, and blood pressure
Initial internal testing has shown promising results:
91.3% classification accuracy in identifying glucose ranges
93.5% sensitivity for detecting hypoglycemia
97.2% specificity for hypoglycemia detection
92.6% of readings in Zone A and 7.1% in Zone B on Clarke Error Grid analysis
The device is currently undergoing formal clinical trials to validate these results in real-world conditions. KOS AI aims to make the Argus available to consumers in Q3 2025, with a version for clinical healthcare providers planned for release by the end of the year.
This non-invasive glucose monitoring technology has the potential to transform diabetes management for millions of people worldwide, offering a painless, continuous, and more convenient alternative to traditional finger prick tests.
Media ContactCompany Name: Nexus PREmail: Send EmailCountry: United StatesWebsite: nexuspr.com
